Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 8/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 8/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL797984 | 0.88 | CYP4F2 (0.60) | CYP4F2CYP4A11P4HBTDP1 | |
| SCHEMBL798199 | 0.88 | CYP4F2 (0.60) | CYP4F2CYP4A11P4HBTDP1 | |
| SCHEMBL798227 | 0.88 | CYP4F2 (0.60) | CYP4F2CYP4A11P4HBTDP1 | |
| SCHEMBL798441 | 0.88 | CYP4F2 (0.60) | CYP4F2CYP4A11P4HBTDP1 | |
| SCHEMBL5705263 | 0.86 | CYP4F2 (0.47) | CYP4F2CYP4A11P4HB | |
| SCHEMBL20816127 | 0.85 | CYP4F2 (0.47) | CYP4F2CYP4A11TBXAS1P4HB | |
| SCHEMBL23970732 | 0.84 | CYP4F2 (0.48) | CYP4F2CYP4A11 | |
| SCHEMBL23971376 | 0.84 | CYP4F2 (0.48) | CYP4F2CYP4A11 | |
| SCHEMBL22071018 | 0.84 | CYP4F2 (0.66) | CYP4F2CYP4A11P4HBTDP1 | |
| SCHEMBL25996655 | 0.83 | CYP4F2 (0.68) | CYP4F2CYP4A11P4HBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142178-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142178-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140121267-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-01 | — | — | US | disclosed |
| US-20140121267-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-01 | — | — | US | disclosed |
| US-8623897-B2 | Methods and compositions for treatment of diabetes and dyslipidemia | KAREUS THERAPEUTICS, SA (CH) | 2014-01-07 | — | — | US | disclosed |
| US-8623897-B2 | Methods and compositions for treatment of diabetes and dyslipidemia | KAREUS THERAPEUTICS, SA (CH) | 2014-01-07 | — | — | US | disclosed |
| WO-2012040177-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071528-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071528-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071528-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | LIPC, PNLIP, LIPA | CYP4F2 361/4885CYP4A11 66/4885TBXAS1 555/4885 |
| US-20140121267-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | GPR119, FFAR1, INSR | CYP4F2 1151/4885CYP4A11 145/4885TBXAS1 716/4885 |
| US-20140142178-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | DHCR7, INSR, GPR119 | CYP4F2 1069/4885CYP4A11 289/4885TBXAS1 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.